RxDoctor Payments Data

Kimberly Lovelady

Family · Marion, INNPI 1912333279

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 86 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$560
  • Lilly USA, LLC$176
  • AbbVie$162
  • Phathom Pharmaceuticals, Inc.$155
  • Novo Nordisk$75
  • Inspire Medical Systems, Inc.$67
  • plus $105 from 3 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,301 in reported general payments places this provider in the 70th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$64,818
Medicare patients
211
Services billed
1,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$146,819
JardianceEmpagliflozin96$79,152
EliquisApixaban83$77,923
JanuviaSitagliptin Phosphate53$65,809
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$60,836
KerendiaFinerenone57$45,649
MounjaroTirzepatide35$44,664
TrulicityDulaglutide20$25,013
Breo ElliptaFluticasone/Vilanterol37$24,069
Tresiba Flextouch U-200Insulin Degludec18$18,610
FarxigaDapagliflozin Propanediol14$12,911
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$12,014
Janumet XrSitagliptin Phos/Metformin Hcl14$10,848
MyrbetriqMirabegron12$10,738
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$10,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$75$146,81992 claims
PfizerEliquis$20$77,92383 claims
Lilly USA, LLCMounjaro, Trulicity$176$69,67655 claims
BayerKerendia$560$45,64957 claims
Phathom Pharmaceuticals, Inc.Voquezna$155$6,92111 claims
AbbVieSynthroid$162$1,59332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,392 family providers in Indiana.

Other family in Marion

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →